Difference between revisions of "Team:Peking/JudgingCriteria"

 
(17 intermediate revisions by 5 users not shown)
Line 7: Line 7:
 
   <meta name="Peking-iGEM-2015" content="iGEM - Peking iGEM 2015">
 
   <meta name="Peking-iGEM-2015" content="iGEM - Peking iGEM 2015">
 
   <!--add  ?action=raw&amp;ctype=text/css    when using Css-->
 
   <!--add  ?action=raw&amp;ctype=text/css    when using Css-->
−
   <link rel="stylesheet" href="https://2015.igem.org/Template:Peking/CSS?action=raw&amp;ctype=text/css" type="text/css" media="screen">
+
   <link rel="stylesheet" href="https://2015.igem.org/Template:Peking/new?action=raw&amp;ctype=text/css" type="text/css" media="screen">
−
   <link rel="stylesheet" type="text/css" href="https://2015.igem.org/Template:Peking/CSS/Style?action=raw&amp;ctype=text/css" media="screen">
+
   <link rel="stylesheet" type="text/css" href="https://2015.igem.org/Template:Peking/Style/new?action=raw&amp;ctype=text/css" media="screen">
−
   <link rel="stylesheet" type="text/css" href="https://2015.igem.org/Template:Peking/CSS/Responsive?action=raw&amp;ctype=text/css" media="screen">
+
   <link rel="stylesheet" type="text/css" href="https://2015.igem.org/Template:Peking/Responsive/new?action=raw&amp;ctype=text/css" media="screen">
−
   <link rel="stylesheet" type="text/css" href="https://2015.igem.org/Template:Peking/CSS/Animate?action=raw&amp;ctype=text/css" media="screen">
+
   <link rel="stylesheet" type="text/css" href="https://2015.igem.org/Template:Peking/Animate/new?action=raw&amp;ctype=text/css" media="screen">
−
   <link rel="stylesheet" type="text/css" href="https://2015.igem.org/Template:Peking/Blue?action=raw&amp;ctype=text/css " title="blue" media="screen" />
+
   <link rel="stylesheet" type="text/css" href="https://2015.igem.org/Template:Peking/Blue/new?action=raw&amp;ctype=text/css " title="blue" media="screen" />
 
   <style type="text/css">/*get rid of the annoying iGEM style*/
 
   <style type="text/css">/*get rid of the annoying iGEM style*/
 +
#top_menu_inside, #top_menu_inside:before, #top_menu_inside:after { -webkit-box-sizing: content-box; -moz-box-sizing: border-box; box-sizing: content-box;}
 +
        #top_menu_under{font-size: 12px;}
 +
        #top_menu_14{font-size: 12px; height:18px}
 +
        #top_menu_inside li{font-size: 12px;}
 +
        #user_item{font-size: 12px;}
 
       #content{padding:0;border:0;width:100%;}
 
       #content{padding:0;border:0;width:100%;}
 
       .firstHeading{visibility:hidden;}
 
       .firstHeading{visibility:hidden;}
Line 28: Line 33:
 
     }
 
     }
 
     .back-to-top{z-index:9999;}
 
     .back-to-top{z-index:9999;}
 +
      ul.dropdown{margin-left: 0px; margin-top: 0px;}
 +
    .classic-title span {
 +
    position: absolute;
 +
    margin-top: -30px;
 +
    border-bottom-color: #00afd1;
 +
}
 +
.page-banner{
 +
  background-color:#e0e0e0;margin-top:1%;margin-bottom:20px;padding:20px;padding-top:40px;
 +
}
 +
 
     </style>
 
     </style>
 
</head>
 
</head>
Line 51: Line 66:
 
                     <div class="navbar-collapse collapse"  style="padding-top:5px;padding-bottom:0">
 
                     <div class="navbar-collapse collapse"  style="padding-top:5px;padding-bottom:0">
 
                         <!-- Start Navigation List -->
 
                         <!-- Start Navigation List -->
−
                         <ul class="nav navbar-nav navbar-right " style="padding-bottom:15px;height:88px;padding-top:10px">
+
                         <ul class="nav navbar-nav navbar-right " style="padding-bottom:15px;padding-top:10px">
 
                             <li>
 
                             <li>
 
                                 <a href="https://2015.igem.org/Team:Peking/JudgingCriteria">Achievements</a>
 
                                 <a href="https://2015.igem.org/Team:Peking/JudgingCriteria">Achievements</a>
Line 68: Line 83:
 
                                     <li><a href="https://2015.igem.org/Team:Peking/Design">Overview</a>
 
                                     <li><a href="https://2015.igem.org/Team:Peking/Design">Overview</a>
 
                                     </li>
 
                                     </li>
−
                                     <li><a href="#">CRIPSR</a>
+
<li><a href="https://2015.igem.org/Team:Peking/Design/PC_Reporter">Paired<span style="text-transform:lowercase"> d</span>Cas9 Reporter</a>                                   
 +
</li>
 +
                                    <li><a href="https://2015.igem.org/Team:Peking/Design/Isothermal">Iso-<span style="text-transform:lowercase">t</span>hermal Amplification</a></li>
 +
                                     <li><a href="https://2015.igem.org/Team:Peking/Device">Hardware</a>
 
                                     </li>
 
                                     </li>
−
                                     <li><a href="#">Isothermal PCR</a>
+
                                     <li><a href="https://2015.igem.org/Team:Peking/Design/Speculation">Speculation</a>
−
                                    </li>
+
−
                                    <li><a href="#">B. subtillis</a>
+
−
                                    </li>
+
−
                                    <li><a href="#">Device</a>
+
 
                                     </li>
 
                                     </li>
 
                                 </ul>
 
                                 </ul>
 
                             </li>
 
                             </li>
 
                             <li>
 
                             <li>
−
                                 <a href="https://2015.igem.org/Team:Peking/Modeling">Modelling</a>
+
                                 <a href="https://2015.igem.org/Team:Peking/Modeling">Modeling</a>
 
                                 <ul class="dropdown">
 
                                 <ul class="dropdown">
−
                                     <li><a href="#">Link 1</a>
+
                                     <li><a href="https://2015.igem.org/Team:Peking/Modeling">Array Design</a>
 
                                     </li>
 
                                     </li>
−
                                     <li><a href="#">Link 2</a>
+
                                     <li><a href="https://2015.igem.org/Team:Peking/Modeling/Analysis">Analysis Algorithm</a>
 
                                     </li>
 
                                     </li>
 
                                 </ul>
 
                                 </ul>
 
                             </li>
 
                             </li>
 
                             <li>
 
                             <li>
−
                                 <a class="active" href="https://2015.igem.org/Team:Peking/Practices">Practices</a>
+
                                 <a href="https://2015.igem.org/Team:Peking/Practices">Practices</a>
 
                                 <ul class="dropdown">
 
                                 <ul class="dropdown">
 
                                     <li><a href="https://2015.igem.org/Team:Peking/Practices">Overview</a>
 
                                     <li><a href="https://2015.igem.org/Team:Peking/Practices">Overview</a>
 
                                     </li>
 
                                     </li>
−
                                     <li><a href="#">TB Facts</a>
+
                                     <li><a href="https://2015.igem.org/Team:Peking/Practices/Background">TB Facts</a>
 
                                     </li>  
 
                                     </li>  
−
                                     <li><a  class="active" href="https://2015.igem.org/Team:Peking/Practices/Consultation">Consultation and Interview</a>
+
                                     <li><a  href="https://2015.igem.org/Team:Peking/Practices/Consultation">Consultation and Interview</a>
 
                                     </li>
 
                                     </li>
 
                                     <li><a href="https://2015.igem.org/Team:Peking/Practices/Engagement">Public Engagement</a>
 
                                     <li><a href="https://2015.igem.org/Team:Peking/Practices/Engagement">Public Engagement</a>
 
                                     </li>
 
                                     </li>
−
                                     <li><a href="https://2015.igem.org/Team:Peking/Practices/Outreach">Ethics and Economics Issue</a>
+
                                     <li><a href="https://2015.igem.org/Team:Peking/Practices/Outreach">Ethics and Economics Issues</a>
 
                                     </li>
 
                                     </li>
 
                                 </ul>
 
                                 </ul>
 
                             </li>
 
                             </li>
 
                             <li>
 
                             <li>
−
                                 <a href="https://2015.igem.org/Team:Peking/Team">Lab</a>
+
                                 <a class="active" href="https://2015.igem.org/Team:Peking/Team">Lab</a>
 
                                 <ul>
 
                                 <ul>
 
                                     <li><a href="https://2015.igem.org/Team:Peking/Team">Team</a>
 
                                     <li><a href="https://2015.igem.org/Team:Peking/Team">Team</a>
Line 109: Line 123:
 
                                     <li><a href="https://2015.igem.org/Team:Peking/Notebook">Notebook</a>
 
                                     <li><a href="https://2015.igem.org/Team:Peking/Notebook">Notebook</a>
 
                                     </li>
 
                                     </li>
−
                                     <li><a href="https://2015.igem.org/Team:Peking/Attributions">Attributions</a>
+
                                     <li><a class="active" href="https://2015.igem.org/Team:Peking/Attributions">Attributions</a>
 
                                     </li>
 
                                     </li>
 
                                     <li><a href="https://2015.igem.org/Team:Peking/Safety">Safety</a>
 
                                     <li><a href="https://2015.igem.org/Team:Peking/Safety">Safety</a>
Line 127: Line 141:
 
      
 
      
 
     <!-- Start Page Banner -->
 
     <!-- Start Page Banner -->
−
     <div class="page-banner" style="background-color:#e0e0e0;margin-top:1%;margin-bottom:20px;padding:20px">  
+
     <div class="page-banner">  
 
       <div class="container">
 
       <div class="container">
 
         <div class="row">
 
         <div class="row">
 
           <div class="col-md-6">
 
           <div class="col-md-6">
−
             <h2 style="font-size:20px; margin-bottom:5px; padding-bottom:0"><b>Practices</b></h2>
+
             <h2 style="font-size:20px; margin-bottom:5px; padding-bottom:0;">J<span style="text-transform:lowercase">udging Criteria</span></h2>
−
             <p style="margin-top:0px;font-size:14px">Study how our work affects the world, and how the world affects our work.</p>
+
             <p style="margin-top:0px;font-size:14px" id="member">Why we deserve gold medal.</p>
 
           </div>
 
           </div>
 
           <div class="col-md-6">
 
           <div class="col-md-6">
 
             <ul class="breadcrumbs">
 
             <ul class="breadcrumbs">
 
               <li><a href="https://2015.igem.org/Team:Peking">Home</a></li>
 
               <li><a href="https://2015.igem.org/Team:Peking">Home</a></li>
−
               <li>Practices</li>
+
               <li>Lab</li>
 
             </ul>
 
             </ul>
 
           </div>
 
           </div>
Line 145: Line 159:
 
     <!-- End Page Banner -->
 
     <!-- End Page Banner -->
  
−
      <div id="content">
+
  <!-- Start Content -->
 +
    <div id="content">
 
       <div class="container">
 
       <div class="container">
 
         <div class="row blog-page">
 
         <div class="row blog-page">
Line 153: Line 168:
 
             <!-- Categories Widget -->
 
             <!-- Categories Widget -->
 
             <div id="sidebar1"class="widget widget-categories">
 
             <div id="sidebar1"class="widget widget-categories">
−
               <h4 style="font-size:18px">Ethic and Economic Issues <span class="head-line"></span></h4>
+
               <h4 style="font-size:18px">A<span style="text-transform:lowercase">chievements</span> <span class="head-line"></span></h4>
 
                 <ul>
 
                 <ul>
 
                 <li>
 
                 <li>
−
                   <a href="#Doctor LI">Ethic Discussion</a>
+
                   <a href="#" style="color:#00afd1">Judging Criteria</a>
 
                 </li>
 
                 </li>
 
                 <li>
 
                 <li>
−
                   <a href="#Director LAO">Economic Analysis</a>
+
                   <a href="https://2015.igem.org/Team:Peking/Parts">Parts</a>
 +
                </li>
 +
                <li>
 +
                  <a href="https://2015.igem.org/Team:Peking/Collaborations">Collaborations</a>
 
                 </li>
 
                 </li>
−
               
 
−
             
 
 
               </ul>
 
               </ul>
 
             </div>
 
             </div>
 +
 
             <div id="sidebar2"class="widget widget-categories">
 
             <div id="sidebar2"class="widget widget-categories">
−
               <h4 style="font-size:18px">Literature Investigation and Economical Assessment <span class="head-line"></span></h4>
+
               <h4>A<span style="text-transform:lowercase">chievements</span> <span class="head-line"></span></h4>
−
                  <ul>
+
                <ul>
 
                 <li>
 
                 <li>
−
                   <a href="#Doctor LI">Ethic Discussion</a>
+
                   <a href="#" style="color:#00afd1">Judging Criteria</a>
 
                 </li>
 
                 </li>
 
                 <li>
 
                 <li>
−
                   <a href="#Director LAO">Economic Analysis</a>
+
                   <a href="https://2015.igem.org/Team:Peking/Parts">Parts</a>
 +
                </li>
 +
                <li>
 +
                  <a href="https://2015.igem.org/Team:Peking/Collaborations">Collaborations</a>
 
                 </li>
 
                 </li>
−
               
 
−
             
 
 
               </ul>
 
               </ul>
 
             </div>
 
             </div>
 
           </div>
 
           </div>
 
           <!--End sidebar-->
 
           <!--End sidebar-->
−
<!-- Page Content -->
+
 
−
           <div class="col-md-9 page-content">
+
          <!-- Page Content -->
−
             <div id="practices">
+
           <div class="col-md-9 page-content" style="text-align:justify;">
 +
             <div id="Judging Criteira">
 
             <!-- Classic Heading -->
 
             <!-- Classic Heading -->
−
              <div id="outreach">
+
      <h3 class="classic-title" style="margin-top:20;"><span>Judging Criteria</span></h3>
−
                <div>
+
<div>
−
                 
+
            <P>We are very proud of the many achievements we have made in this summer. Here is a compilation of our feats! </P>
−
                  <h3 class="classic-title" style="margin-top:50px"><span>Ethics Discussion</span></h3>
+
<P>1. We successfully designed and constructed a paired dCas9 reporter (PC Reporter) that can convert specific sequence information into light signal; the detailed characterization showed that it was effective for real TB nucleic acid diagnosis. (For more details, <a href="https://2015.igem.org/Team:Peking/Design/PC_Reporter" style="color:#00afd1">click here</a>)</P>
−
                  <div style="margin-top:30px; margin-bottom:20px;padding-bottom:20px">
+
<P>
−
                  <div style="padding-bottom:20px">
+
2. We submitted 21 high-quality and well-characterized Standard Biobricks, including a set of paired dCas9 reporter collection. (For more details, <a href="https://2015.igem.org/Team:Peking/Parts" style="color:#00afd1">click here</a>)</P>
−
                      <div class="col-md-6">
+
<P>
−
                    <img src="https://static.igem.org/mediawiki/2015/1/18/Peking-Ethics-1.jpg">
+
3. We successfully designed an MTB multi-marker array to deal with challenges from clinical practices, such as strain mutations, sample variations, and other uncontrollable environmental factors. (For more details, <a href="https://2015.igem.org/Team:Peking/Modeling" style="color:#00afd1">click here</a>)</P>
−
                      </div>
+
<P>
−
                    <p>Synthetic biology, as a newly-presented subdiscipline of life sciences, has appealed to lots of researchers devoting themselves to it. As the world has got insights into the information covered by the genes, they’ve mastered their biological functions. It is just like an engineering job that these biobricks are assembled by synthetic biologists to become a biological device, which can complete novel tasks. From the moment it emerged, it moved towards the public accompanied by many controversial topics. A large portion of people stoutly negates the field with the thought that it is as frightening as ‘human cloning’.
+
4. A portable and affordable Ultra-Sensitive Bioluminescence Detector (USB Detector) was built for convenient detection of light read-outs. (For more details, <a href="https://2015.igem.org/Team:Peking/Device" style="color:#00afd1">click here</a>)
−
                    </p>
+
</P>
−
                    <p>At the present, the basic ideas in synthetic biology include two lines. One is to design and construct new biological parts, modules and system. The other is to redesign the existing and natural biosystem. Both ideas are for benefits of human society. Obviously its task is to standardize the gene bioinformation, and manufacture operable standard bioparts. However, it seems at the opposite sides with the biodiversity of the nature. How can we resolve this kind of contradiction? And how do our human beings look upon the numerous social problems it causes such as the patents and impartiality?
+
<P>5. We invented one new isothermal amplification method to expand existing isothermal PCR methods. (For more details, <a href="https://2015.igem.org/Team:Peking/Design/Isothermal" style="color:#00afd1">click here</a>)
−
                    </p>
+
</P>
−
                   
+
<P>6. We visited doctors and experts from the research institute for TB control and local hospitals to learn the situation of TB and their demands for TB detection. After finishing main work, we presented them with our achievements and got their feedback. (For more details, <a href="https://2015.igem.org/Team:Peking/Practices/Consultation" style="color:#00afd1">click here</a>)
−
                    <p>The ultimate aim of synthetic biology is to synthesis a completely artificial life, which is notwithstanding fascinated to many of us. Nevertheless, it makes the whole society feel terrified to the unknown vita. In that way, whether or not we should advocate this kind of creativity for life? And how can we evaluate the benefits and risks in synthetic biology? Or how can human beings find a balance point of the double-edged sword?
+
</P>
−
                    </p>
+
<P>7. We did an ethics discussion and finished an economic report about future TB detection. We enhanced the public education about TB and synthetic biology by doing survey, distributing brochures and giving lectures. (For more details, <a href="https://2015.igem.org/Team:Peking/Practices/Outreach" style="color:#00afd1">click here</a>)
−
                    <p>To find the answers to all the above questions, we’ve conducted a discussion on the ethical issues in synthetic biology with Doctor Xie Guangkuan of the Institute of Medical Humanities of PKU. At the same time, we estimated our project on ethics according to the Four Principles of Bioethics.
+
</P>
−
                   
+
<P>8. We helped and collaborated with 5 other iGEM teams by guiding new teams, discussing about project design and technical skills and sharing DNA materials. (For more details, <a href="https://2015.igem.org/Team:Peking/Collaborations" style="color:#00afd1">click here</a>)
−
                    </p>
+
</P>
−
                    <div class="col-md-12" style="padding-bottom:20px">
+
<P>9. We successfully hold CCiC (Conference of China iGEMer Committee). It's a large-scale competition-free jamboree for 34 teams, providing participants with an opportunity for meaningful exchanges in ideas and problem solving. (For more details, <a href="https://2015.igem.org/Team:Peking/Collaborations" style="color:#00afd1">click here</a>)
−
                    <img src="https://static.igem.org/mediawiki/2015/8/80/Peking-Ethics-2.jpg">
+
</P>
−
                    </div>
+
<P>Therefore, we believe that we deserve a Gold Medal Prize.</P>
−
                    </div>
+
−
                   
+
−
                    <h5>The First Principle: BENEFICENCE</h5>
+
−
                   
+
−
                    <p>Compared with other traditional detection methods, the biggest advantage of the detection of nucleic acid is the great shortened of the time without the decrease of the specificity and sensitivity. And not to mention the influence of time cost on the economy of a gradually developed society, only consider its role in the prevention and cure of tuberculosis is enough to make people wonder. In the diagnosis and treatment of TB, traditional methods, such as bacteriological detection methods, need one to two months to get the result, while in clinical work, no doctors dare to give treatment after such a long time waiting for the result, because the disease may develop rapidly during the waiting time, which may lead to irreversible consequences. Therefore, in the current clinical work in China, treatment would be given first while waiting for the detection result of bacterial culture. This is indeed a way to avoid the development of the disease, but for the misdiagnosis patients, on the one hand, the right treatment has been delayed, on the other hand, the wrong treatment may lead to the resistance to anti-tuberculosis drugs. Nucleic acid detection can effectively avoid these problems, the existing mature detection technology of Mycobacterium tuberculosis usually takes only a few hours to get the result, which can greatly reduce the detection time and is more conducive to the realization of the treatment after diagnosis, which thus can avoid delay treatment and error treatment.
+
−
                    </p>
+
−
                    <p>Although nucleic acid detection has much advantage compared to traditional detection method, the detection of nucleic acid is still not able to replace the traditional detection method. The main reason owes to its expensive price. Besides that, the traditional detection method has been developed for many years, and through the traditional detection, the staffs can see mycobacterium tuberculosis directly, which give them more confidence on making a definite diagnosis. Thus as a new method which gives the result through an indirect way, nucleic acid detection method is refused from the idea of part of doctors. And in this paper, we will focus primarily on the former: the advantages and disadvantages of nucleic acid detection in the economic analysis compared with the traditional detection method. Through consulting Beijing research institute for tuberculosis control, we have learned that the current traditional smear technology price is about 15 yuan, and 60 yuan for bacterial culture, that is, the price of  traditional detection method is about 100 yuan, and the current method for nucleic acid detection such as Hans needs 525 yuan, X-pert detection technology needs 650 yuan, which means the detection method of nucleic acid is about 5-6 times as much as the price of traditional methods, leading to the conflict psychology for patients to use nucleic acid detection method. In addition, as for the hospital, the cost of traditional detection method is relatively low, while providing nucleic acid detection method, hospitals need to be equipped with more expensive equipment, according to the introduction of the lab director from Beijing research institute for tuberculosis control, the construction of the current nucleic acid detection platform costs tens of thousands or even hundreds of thousands, although most large hospitals have the ability to afford this instrument. However, for small or medium hospitals, it is still difficult to be equipped with such expensive instruments. And dramatically, the incidence of tuberculosis in China in rural areas is much higher than urban areas, which means most of the tuberculosis patients cannot use nucleic acid detection method. Thus no matter from the view of hospital or patient, the use of nucleic acid testing is out of affording, which leads to the limitation of its application.  
+
−
                    </p>
+
−
                 
+
−
                    <P>And our project which is also based on nucleic acid detection has given a clever solution to the problem. We concentrate the detection process in a handy container. The first to avoid the need for nucleic acid detection laboratory platform, which thus can solve the problem for small hospitals to withstand the high cost of laboratory established. On the other hand, our instrument uses a new principle of work and cost much lower compared with the previous nucleic acid detection method.
+
−
                    </P>
+
−
                    <P>And our project which is also based on nucleic acid detection has given a clever solution to the problem. We concentrate the detection process in a handy container. The first to avoid the need for nucleic acid detection laboratory platform, which thus can solve the problem for small hospitals to withstand the high cost of laboratory established. On the other hand, our instrument uses a new principle of work and cost much lower compared with the previous nucleic acid detection method.
+
−
                    </P>
+
−
                    <h5>The Second Principle: EQUITY</h5>
+
−
                  <div class="col-md-4" style="padding-right:20px">
+
−
                  <img src="https://static.igem.org/mediawiki/2015/f/fb/Peking-Outreach-Ethics-4.jpg">
+
−
                  </div>
+
−
                  <p>Whether in China or in the world, the gap between the rich and the poor, the inequality of regional resources is a problem that we cannot ignore. When the unequal distribution of resources comes to the diagnosis of Mycobacterium tuberculosis, the incidence of tuberculosis is getting worse caused by the delayed diagnosis of tuberculosis in relatively backward regions. We take Beijing research institute for tuberculosis control and the Center for Disease Control of ZhengHe in Fujian Province as the representative of the developed cities and remote mountainous areas, and detailed consultation with the two agencies have been made. As expected, Beijing research institute for tuberculosis control has a variety of innovative nucleic acid testing equipment, although they said these devices are indeed expensive, not often used in clinical, but they have these conditions. And for Center for Disease Control of ZhengHe in Fujian province, it has only the traditional detection facilities, no conditions to build a nucleic acid detection platform. What’s worse, for the region's people, the majority have no economic ability to bear the cost of nucleic acid detection. This has led to the unfairness in the detection of Mycobacterium tuberculosis, and the economic level is the detection means of the watershed.
+
−
                  </p>
+
−
                 
+
−
                  <P>As stated above, our project is trying to put a set of nucleic acid detection in a small container, in line with the concept of Point-Of-Care, making a detection which is cheap, convenient and simple. Such a set of equipment will be able to minimize the embarrassment brought by the differences in the region. And the relatively backward areas can have the opportunity to use the new methods to reduce the time of the detection of tuberculosis, and improve the detection specificity and sensitivity, even in the absence of qualified laboratory conditions.</P>
+
  
−
                  <h5>The Third Principle: RESPECT</h5>
+
        </div>
−
                  <P>As a country whose incidence of tuberculosis is ranked second in the world, there are lots of TB patients in China. And according to the relevant laws and regulations in China, the TB patients are limited in certain industries such as teachers. In catering and other industries, people are required to have the certificate issued by the hospital to prove they are not the TB patients. If TB detection becomes easier, it is expected that this part of unit can be equipped with such a testing tool for practitioners to verify, and even other industries will hope that their employees are not TB patients, thus they may be equipped with the appropriate testing tools as well. Although doing so is beneficial to the control of tuberculosis, it can also make the patients feel that their privacy is not protected, and they may feel social discrimination and disrespect. For this case, we do not think that it can be the reason for the detection of nucleic acids should be fixed. The state should take other measures, such as the restriction of enterprise or institution to buy such disease detection tools, etc.
+
−
                  </P>
+
  
−
                  <h5>CONCLUSION</h5>
 
−
                  <P>To sum up, we believe that the project we are working on is in line with the principles of ethics, which will help promote human health, and to some extent improve the imbalance of social medical resources.
 
−
                  </P>
 
−
                  <div class="col-md-12">
 
−
                  <img src="https://static.igem.org/mediawiki/2015/2/28/Peking-Outreach-Ethics-5.jpg">
 
−
                </div>
 
−
                </div>
 
−
               
 
  
−
 
−
 
−
                <h3 class="classic-title" style="margin-top:50px"><span>Economics</span></h3>
 
−
                  <div style="margin-top:30px; margin-bottom:0">
 
−
                    <p>The overall goal for control of Tuberculosis (TB) is to ensure prompt identification and treatment of infectious patients, and to eliminate TB ultimately. Global progress was seen in last two decades, but not enough to reach the aim of TB control, where detection method is the major limitation.<br><br>
 
−
There are various detection methods. Sputum smear microscopy remains the mainstay of TB diagnosis in China and other resource-constrained countries, which is inexpensive but not sensitive particularly in people with HIV and in children, while culture serves as the current reference standard but takes weeks and requires laboratory capacity. Rapid molecular tests to diagnose TB and drug-resistant TB such as Xpert requires expensive equipment and trained laboratory staffs, making it not widely adopted in China.<br><br>
 
−
With the low percentage (37%) of new pulmonary cases that were bacteriologically confirmed, China accounted for 11% of the 5.7 million new and relapse cases of TB that were notified in 2013, [1] which has an urgent need for accurate and rapid detection methods. <br><br>
 
−
Peking iGEM 2015 develops a detection device making use of the CRISPR/Cas9 system. It has shown that CRISPR/Cas9 systems can be engineered to direct targeted specific DNA sequence of Mycobacteria tuberculosis by using a mutant of Cas9 nuclease without double-stranded endonuclease activity (dCas9) and two “guide RNA” with complementarity to specific DNA target site screened by bioinformatics. Fusing dCas9 with split reporter proteins, the signal can be easily read out. <br><br>
 
−
 
−
What is the supply and demand relationship in TB testing market? Can our device really be applied to TB diagnosis in China? Is there any possibility that advanced molecular tests will replace traditional methods? Are there other features should our device have? To find the answers to these questions, we’ve conducted a discussion on the economic issues with Mr Ding Beichuan, Director of Center Lab of Beijing Research Institute for Tuberculosis Control.
 
−
 
−
                    </p>
 
−
                    <h4>Supply in TB testing market</h4>
 
−
                    <p>Table 1. Comparison of current diagnosis methods in China</p>
 
−
                    <img src="https://static.igem.org/mediawiki/2015/a/ac/Peking-Outreach-Economics-table.png" style="margin-bottom:0">
 
−
                    <p>(Data sources: Ding Beichuan, Director of Center Lab of Beijing Research Institute for Tuberculosis Control)</p>
 
−
                    <p>Although TB testing is still reliant on traditional tools such as sputum smear microscopy and culture, new detection methods are changing the tuberculosis diagnostics landscape. The 2014 UNITAID TB Diagnostics Technology and Market Landscape report listed the technologies endorsed by WHO[2], stated that it should be noted that the most impressive trend is the application of molecular technologies in TB testing, such as traditional PCR, RT-PCR, Gene microarray and X-pert, which have already entered the Chinese market.<br><br>
 
−
 
−
According to Director Ding, patients using the advanced molecular testing methods accounts for only 4.3% of all patients in Beijing, while sputum smear and culture is still the common method. Of the nucleic acid detection methods, the percentage of X-pert takes up 72%. It is clear that molecular testing method is not as popular as sputum smear and culture in China since sputum culture is much cheaper, which has been regarded as the golden criteria for years and covered by health insurance. However, sputum smear is not sensitive enough particularly in those with HIV and in children. Note that among 7271 cases reported in 2014, only less than 3000 were smear-positive TB.<br><br>
 
−
 
−
Table 2. Comparison of current RT-PCR kits.
 
−
 
−
                    </p>
 
−
                    <img src="https://static.igem.org/mediawiki/2015/8/8f/Peking-Outreach-Economics-table2.png">
 
−
                    <p>(Data sources: )</p>
 
−
                    <p>The principles of current detection methods fall into three categories. Bacteriological methods such as sputum smear microscopy, mycobacteria culture and isolation identification recognize TB directly and identify the species of TB in the meantime. Sputum is cheap but not sensitive enough, while culture serves as reference standard but takes weeks; Immunology method based on detection of antibody in serum is fast and easy to operate but indirect, which is not recommended as a routine diagnostic method by WHO for its low sensitivity and specificity; Molecular biological methods detects specific sequence of TB directly, having the advantage of rapidness and sensitivity. However, its high cost of reagents and requirements on facilities and operating skills is the major obstacle for promotion. Compared with existing detection methods, our device is of sensitivity, specificity, portability and programmability.<br><br>
 
−
 
−
Table 3: Cost and effect of device of Team Peking 2015
 
−
</p>
 
−
                <img src="https://static.igem.org/mediawiki/2015/9/91/Peking-Outreach-Economics-table3.png">
 
 
              
 
              
−
                <img src="https://static.igem.org/mediawiki/2015/9/9c/Peking-Outreach-Economics-table4.png">
+
    </div>
−
                <h4>Demand in TB diagnosis market</h4>
+
−
                <p>China has an urgent demand of reliable TB diagnostic technology. According to the fifth national tuberculosis epidemiological survey, 2010, three features characterize the epidemic situation of tuberculosis in China. (1) Morbidity in rural areas is significantly higher than that in cities, which are 569 and 307 per 100 thousand people respectively. (2) The problem of regional imbalance is severe in the aspect of the prevalence rate. In the western region, manpower resources for TB control are much deficient because of poverty and remoteness. Therefore, these areas require a diagnostic method that is simple and quick, to reduce the morbidity. (3) It is estimated that there are nearly 5 million active pulmonary tuberculosis patients above 15 years old.<br><br>
+
  
−
Institutes in all levels of TB control and hospitals of all types are target customers of our product, particularly community hospitals and clinics, where equipped laboratories and funding are usually lacked. Note that 30 million yuan was invested into institutes of TB control of Beijing, while just 2.5 million yuan for those of Hebei Province.<br><br>
 
−
 
−
Director Ding mentioned that one of the important factors influencing customers’ behaviors is the convenience of operation process. It is supported by the fact that molecular detection methods was popularized by Beijing government since 1994, however, only 2 institutes were equipped with the platform due to its complex operation process and high cost.
 
−
   
 
−
</p>     
 
−
<img src="https://static.igem.org/mediawiki/2015/e/e9/Peking-Outreach-Economics-picture1.png">
 
−
<p>Pic: Features that a detection method supposed to have.
 
−
</p>
 
−
 
−
 
−
 
−
 
−
 
−
 
−
 
−
 
−
 
−
                   
 
−
 
−
 
−
 
−
                </div>
 
−
            </div>
 
−
          </div>
 
−
        </div>
 
−
      </div>
 
−
    </div>
 
 
</div>
 
</div>
−
   
+
</div>
 +
</div>
 +
 
 
      
 
      
 
       <!--FOOTER************FOOTER*******************FOOTER***************FOOTER************-->
 
       <!--FOOTER************FOOTER*******************FOOTER***************FOOTER************-->
Line 319: Line 250:
 
                             <ul class="social-icons" style="padding-top:0:padding-bottom:0;margin-top:0;margin-bottom:0">
 
                             <ul class="social-icons" style="padding-top:0:padding-bottom:0;margin-top:0;margin-bottom:0">
 
                                 <li style="padding-top:0:padding-bottom:0;margin-top:0;margin-bottom:0"><!--HERE need to be changed-->
 
                                 <li style="padding-top:0:padding-bottom:0;margin-top:0;margin-bottom:0"><!--HERE need to be changed-->
−
                                     <a class="twitter" target="_blank" href="https://twitter.com/home/?status=https://2015.igem.org/Team:Peking/Practices/Consultation">
+
                                     <a class="twitter" target="_blank" href="https://twitter.com/home/?status=https://2015.igem.org/Team:Peking">
 
                                       <i class="fa">
 
                                       <i class="fa">
 
                                         <img src="https://static.igem.org/mediawiki/2015/d/d0/Peking-twitter.png" style="height:20px;width:auto; margin-top:7px;">
 
                                         <img src="https://static.igem.org/mediawiki/2015/d/d0/Peking-twitter.png" style="height:20px;width:auto; margin-top:7px;">
Line 326: Line 257:
 
                                 </li>
 
                                 </li>
 
                                 <li style="padding-top:0:padding-bottom:0;margin-top:0;margin-bottom:0"><!--HERE need to be changed-->
 
                                 <li style="padding-top:0:padding-bottom:0;margin-top:0;margin-bottom:0"><!--HERE need to be changed-->
−
                                     <a class="facebook"target="_blank" href="https://www.facebook.com/sharer/sharer.php?u=https://2015.igem.org/Team:Peking/Practices/Consultation">
+
                                     <a class="facebook"target="_blank" href="https://www.facebook.com/sharer/sharer.php?u=https://2015.igem.org/Team:Peking">
 
                                       <i class="fa">
 
                                       <i class="fa">
 
                                         <img src="https://static.igem.org/mediawiki/2015/0/0e/Peking-facebook.png" style="height:20px; margin-top:7px;">
 
                                         <img src="https://static.igem.org/mediawiki/2015/0/0e/Peking-facebook.png" style="height:20px; margin-top:7px;">
Line 333: Line 264:
 
                                 </li>
 
                                 </li>
 
                                 <li style="padding-top:0:padding-bottom:0;margin-top:0;margin-bottom:0"><!--HERE need to be changed-->
 
                                 <li style="padding-top:0:padding-bottom:0;margin-top:0;margin-bottom:0"><!--HERE need to be changed-->
−
                                     <a class="google"target="_blank" href="https://plus.google.com/share?url=https://2015.igem.org/Team:Peking/Practices/Consultation">
+
                                     <a class="google"target="_blank" href="https://plus.google.com/share?url=https://2015.igem.org/Team:Peking">
 
                                       <i class="fa">
 
                                       <i class="fa">
 
                                         <img src="https://static.igem.org/mediawiki/2015/7/7a/Peking-google_plus.png" style="height:20px; margin-top:7px;">
 
                                         <img src="https://static.igem.org/mediawiki/2015/7/7a/Peking-google_plus.png" style="height:20px; margin-top:7px;">

Latest revision as of 06:51, 16 November 2015

Peking iGEM 2015

Judging Criteria

Why we deserve gold medal.

Judging Criteria

We are very proud of the many achievements we have made in this summer. Here is a compilation of our feats!

1. We successfully designed and constructed a paired dCas9 reporter (PC Reporter) that can convert specific sequence information into light signal; the detailed characterization showed that it was effective for real TB nucleic acid diagnosis. (For more details, click here)

2. We submitted 21 high-quality and well-characterized Standard Biobricks, including a set of paired dCas9 reporter collection. (For more details, click here)

3. We successfully designed an MTB multi-marker array to deal with challenges from clinical practices, such as strain mutations, sample variations, and other uncontrollable environmental factors. (For more details, click here)

4. A portable and affordable Ultra-Sensitive Bioluminescence Detector (USB Detector) was built for convenient detection of light read-outs. (For more details, click here)

5. We invented one new isothermal amplification method to expand existing isothermal PCR methods. (For more details, click here)

6. We visited doctors and experts from the research institute for TB control and local hospitals to learn the situation of TB and their demands for TB detection. After finishing main work, we presented them with our achievements and got their feedback. (For more details, click here)

7. We did an ethics discussion and finished an economic report about future TB detection. We enhanced the public education about TB and synthetic biology by doing survey, distributing brochures and giving lectures. (For more details, click here)

8. We helped and collaborated with 5 other iGEM teams by guiding new teams, discussing about project design and technical skills and sharing DNA materials. (For more details, click here)

9. We successfully hold CCiC (Conference of China iGEMer Committee). It's a large-scale competition-free jamboree for 34 teams, providing participants with an opportunity for meaningful exchanges in ideas and problem solving. (For more details, click here)

Therefore, we believe that we deserve a Gold Medal Prize.